UNSPSC 51191705: Citric acid and potassium citrate combination

This classification denotes an alkalinizing agent combination drug. The first component of this drug is a carboxylic acid with the molecular formula C6H8O7.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2968PHW8QPm, and which is called citric acid. European Medicines Agency schedules citric acid monohydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12482MIG. The term citrate is a U.S. FDA designation.

UNSPSC 51191705 Citric acid and potassium citrate combination is a Commodity code that in recent state and local solicitations tracks chemical supply for water treatment and pollution control operations rather than citric acid or potassium citrate specifically. The City of Meriden's IFB for sodium bisulfite (solicitation B027-15, due July 29, 2026) illustrates the actual buying pattern: municipal water pollution control facilities procure treatment chemicals on a unit-cost basis under firm-price bid structures, with General Liability and Auto Liability insurance requirements and performance and payment bonds. State and local water authorities appear to be the primary buyers under this code, although the Minnesota Multistate Cooperative Purchasing Alliance RFP for generic pharmaceuticals and OTC products (solicitation S1070000015802, due March 26, 2026) suggests the code may also capture multi-source chemical and pharmaceutical supply agreements spanning health care and institutional customers across multiple states.

Recent activity is concentrated in the Northeast and Upper Midwest, with Connecticut and Minnesota each represented in the current opportunity set. The City of Meriden's sodium bisulfite procurement reflects routine municipal water treatment chemical supply, while MMCAP's pharmaceutical and OTC RFP—administered by Minnesota's Department of Administration and drawing participation from Oregon and other states—indicates broader cross-jurisdictional procurement for institutional health care and public-health supply chains. The MMCAP contract term runs two years with optional extensions through June 30, 2028, and awards are expected by May 15, 2026. Vendors responding to either opportunity must meet cGMP and FDA compliance standards where applicable and maintain substantial commercial general liability coverage ($1 to $5 million depending on the solicitation).